Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment

ClinicalTrials.gov ID: NCT05458284

Public ClinicalTrials.gov record NCT05458284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Acupuncture for Taxane-Induced Peripheral Neuropathy Prevention (ATP): A Phase II Randomized, Placebo Controlled Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Some people experience a side effect while they are receiving taxane called taxane-induced peripheral neuropathy (TIPN). TIPN is pain in the arms and legs due to nerve damage caused by cancer treatment and may interfere with quality of life. The purpose of this study is to learn if acupuncture can prevent TIPN from getting worse. Acupuncture is a medical technique that involves insertion of very thin needles into specific areas on the body. We will compare real acupuncture (RA) to placebo (sham) acupuncture (SA). SA is done like RA, but will use different needles and target different sites or places on the body than RA. We are comparing RA to SA to learn whether RA can prevent TIPN from getting worse while receiving taxane.

Study identification

NCT ID
NCT05458284
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
80 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 10, 2022
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027
Last update posted
Aug 4, 2026

2022 – 2027

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Bergen Montvale New Jersey 07645
Memorial Sloan Kettering Suffolk- Commack Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Nassau Rockville Centre New York 11553

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05458284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 4, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05458284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →